HCL Technologies Ltd has posted results for the first quarter ended 30th June, 2013.

The net profit for the quarter stood at Rs12.10bn.

Q4 other income was at Rs1.75bn, while sales is at Rs69.44bn.
Total Income has increased from Rs 210370.50 mn for the year ended June 30, 2012 to Rs 258876.70 mn for the year ended June 30, 2013.

The company has announced that the Board of Directors of the Company at its meeting held on July 31, 2013, inter alia, has recommended a final dividend of Rs.6/- per equity share of Rs.2/- each of the Company for the year ended June 30, 2013.
The company said that its Board of Directors has appointed Ms. Roshni Nadar Malhotra as the Additional Director of the Company w.e.f. July 29, 2013.

“Fy’13 results have demonstrated significant business momentum, non- linearity and record customer satisfaction. HCL continues to excel in agility and innovation with a Business Model that is resilient in a dynamic environment,” said Shiv Nadar, Chairman & Chief Strategy Officer, HCL Technologies.
“An exceptional growth of 22% during the Financial Year has propelled HCL’s Revenue past the INR 25000 crore milestone. HCL continues to lead the industry in profitable growth, with seven successive quarters of Net Income Margin expansion, having reported 62% growth in Net Income this year. We have consolidated our leadership position in the Infrastructure Management Services and verticals like Financial Service and Lifesciences & Healthcare,” said Anant Gupta, President & CEO, HCL Technologies.
“Backed by another strong quarter, we closed our Financial Year on a positive note. Our Net Income margin expanded by 400 bps and touched a five year high of 16%. Our Return on Equity for the year has been 34% which is amongst the best in the industry. EBITDA to Free Cash Flow conversion has been at a healthy 68%," said Anil Chanana, CFO, HCL Technologies.
During the quarter, HCL booked in excess of US$ 1 Billion, including 12 multi- year deals from F500/G2000 clients. These were primarily from Manufacturing, Financial Services and Lifesciences & Healthcare verticals. Focus on disruptive new propositions like EFaaSTM, ALT ASM, Enterprise of Future and Innovation Monetization continue to drive our differentiation in the transformational renewal market.